Rialto Wealth Management’s Lantern Pharma LTRN Stock Holding History

Rialto Wealth Management’s Portfolio LTRN Stock Details LTRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$513	Buy	+123	New	+$361	﹤0.01%	1704

Other funds holding LTRN

EAM

Empery Asset Management New York $86.5M AUM

CM Management Gulf Breeze, Florida $157M AUM 60.08% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

BCM

BIOS Capital Management Fort Worth, Texas $41.7M AUM 34.92% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

WIM

Westside Investment Management Santa Monica, California $761M AUM 39.85% 1-Year Est. Return

Quadrature Capital London, United Kingdom $11.7B AUM 87.29% 1-Year Est. Return

Rialto Wealth Management's LTRN Position: Q2 2026 in Review

Rialto Wealth Management opened a new position in Lantern Pharma (LTRN) in Q2 2026: 123 shares worth $513. The stake represents ﹤0.01% of the portfolio and ranks #1704 among its holdings.

39 funds tracked by Wall St. Rank hold LTRN as of Q2 2026.

Rialto Wealth Management held 123 shares of Lantern Pharma worth $513 as of Q2 2026.
Lantern Pharma was a new Rialto Wealth Management position in Q2 2026.
Lantern Pharma made up ﹤0.01% of Rialto Wealth Management's portfolio in Q2 2026, its #1704 holding.
39 funds tracked by Wall St. Rank held Lantern Pharma as of Q2 2026.

Based on Rialto Wealth Management's 13F filing for Q2 2026, filed 11 Aug 2026.